[Digital Daily Reporter Kim Bo-min] Hippo T&C, a digital therapeutics company, will collaborate with Samsung Seoul Hospital in the field of digital therapeutic devices.

Hippo T&C (CEO Tai-Myoung Chung) announced on the 29th that it had signed a Memorandum of Understanding (MoU) with Samsung Seoul Hospital's Digital Therapeutics Research Center (headed by Professor Hong-Jin Jeon) to "collaborate on the development and research enhancement of digital therapeutic devices."

This collaboration is based on the "K-DEM Station for the development of digital therapeutic devices and electronic medicines," a research and development (R&D) support project by the Ministry of Health and Welfare aimed at fostering research-oriented hospitals.

Through this agreement, Hippo T&C and Samsung Seoul Hospital's Digital Therapeutics Research Center expect to expand their exchange in areas such as ▲research and development of digital therapeutic device technology ▲clinical safety and efficacy studies of digital therapeutic devices ▲provision and maintenance of digital therapeutic devices.

Hippo T&C gained attention as a specialized digital therapeutics company after receiving an Innovation Award at the IT and home appliance exhibition 'CES 2022' held in Las Vegas, USA. Currently, two types of digital therapeutics (the depression treatment "BlueKare" and the ADHD diagnostic tool "AttnKare-D"), developed in collaboration with leading domestic and international experts, are undergoing confirmatory clinical trials for approval by the Ministry of Food and Drug Safety (MFDS) and are also in the process of obtaining FDA 510(k) clearance for entry into the U.S. market.

Tai-Young Chung, CEO of Hippo T&C, said, "The collaboration with Samsung Seoul Hospital, which has the highest capabilities in the field of digital therapeutics research, will enable us to provide higher-quality services."

Professor Hong-Jin Jeon, Vice Dean of the School of Medicine at Sungkyunkwan University and Director of the Digital Therapeutics Research Center, stated, "We are delighted to be part of the process of innovating medical paradigms based on digital therapeutics with a growing specialized company."

Meanwhile, Hippo T&C, which owns a VR-based diagnostic and therapeutic tool for Attention Deficit Hyperactivity Disorder (ADHD), will launch a depression prevention mobile app called "WithBuddy" on September 2. WithBuddy provides features such as AI counseling, meditation, and deep breathing through interaction with a virtual pet, an AI companion.

It is a new type of app service that helps users take care of their mental health through objective self-assessment before falling into depression. Through WithBuddy, Hippo T&C aims to offer a hopeful solution for modern individuals concerned about stress, anxiety, and depression.

Original Source : ddaily(https://www.ddaily.co.kr/page/view/2024082916540352952)

This article is a translation of a Korean original into English.